Utilizing Different Mechanisms of Action for Treatment of Chronic Graft-Versus-Host Disease

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.

EP. 1: Acute Versus Chronic Graft-Versus-Host Disease (GVHD)

January 11th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.

EP. 2: Phases of Pathophysiology of Chronic GVHD

January 11th 2024

The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.

EP. 3: Monitoring Patients with GVHD

January 18th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss challenges in detecting and diagnosing chronic GVHD. The panel advocates for vigilant communication, early detection, and ongoing patient education for comprehensive post-transplant care.

EP. 4: Expectations of Chronic GVHD Treatment

January 18th 2024

The panel reviews recent developments in treatments, therapeutic approaches post-transplant, and the importance of clear communication in navigating patient expectations.

EP. 5: Targeted Treatments for GVHD

January 25th 2024

The GVHD experts discuss recent advancements in chronic GVHD treatment, focusing on agents ruxolitinib, ibrutinib, and belumosudil and their mechanisms of action. The panel emphasizes the need for ongoing research and clinical trials to refine treatment strategies.

EP. 6: Corticosteroids and Clinical Trial Design in Chronic GVHD

January 25th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the complexities of chronic GVHD management, highlighting recent developments and efforts to reduce reliance on steroids.

EP. 7: Switching to Second Line Treatment in Chronic GVHD

February 2nd 2024

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

EP. 8: Ruxolitinib in Chronic GVHD

February 2nd 2024

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

EP. 9: Ibrutinib in Chronic GVHD

February 8th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

EP. 10: Belumosudil for Treatment of Chronic GVHD

February 8th 2024

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

EP. 11: A GVHD Clinical Scenario

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

EP. 12: Third Line Treatment in Chronic GVHD

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

EP. 13: Emerging Agents in GVHD: Axatilimab

February 22nd 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

EP. 14: Future Landscape of Chronic GVHD

February 22nd 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

EP. 15: Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD

February 29th 2024

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

EP. 16: Practical Advice for Management of Chronic GVHD

February 29th 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.